相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature
Fausto Meriggi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Combined in vitro IL-12 and IL-15 stimulation promotes cellular immune response in dogs with visceral leishmaniasis
Sidnei Ferro Costa et al.
PLOS NEGLECTED TROPICAL DISEASES (2020)
Cytokines in the Treatment of Cancer
Kevin C. Conlon et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
Jake S. O'Donnell et al.
CLINICAL CANCER RESEARCH (2019)
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
Paul A. Cohen et al.
GYNECOLOGIC ONCOLOGY (2019)
Ovarian Cancer Immunotherapy: Turning up the Heat
Eleonora Ghisoni et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Krishnansu S. Tewari et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-γ
Lin Lin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
GEN-1 immunotherapy for the treatment of ovarian cancer
Premal H. Thaker et al.
FUTURE ONCOLOGY (2019)
Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells
Qi Lai et al.
ONCOGENE (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma
Aras Toker et al.
CLINICAL CANCER RESEARCH (2018)
Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
S. J. L. Mesnage et al.
ANNALS OF ONCOLOGY (2017)
Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
Charlotte S. Lo et al.
CLINICAL CANCER RESEARCH (2017)
Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection
Renee Turzanski Fortner et al.
GYNECOLOGIC ONCOLOGY (2017)
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study
Premal H. Thaker et al.
GYNECOLOGIC ONCOLOGY (2017)
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Weimin Wang et al.
CELL (2016)
Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Steffen Bohm et al.
CLINICAL CANCER RESEARCH (2016)
Minireview: Regulatory T Cells and Ovarian Cancer
Manindra Singh et al.
IMMUNOLOGICAL INVESTIGATIONS (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Sean Kehoe et al.
LANCET (2015)
New insights into IL-12-mediated tumor suppression
S. Tugues et al.
CELL DEATH AND DIFFERENTIATION (2015)
Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer
Khursheed Anwer et al.
GYNECOLOGIC ONCOLOGY (2013)
Cancer treatment and survivorship statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Differential Effects of IL-12 on Tregs and Non-Treg T Cells: Roles of IFN-γ, IL-2 and IL-2R
Jingxian Zhao et al.
PLOS ONE (2012)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Neoadjuvant Chemotherapy Is the Better Treatment Option in Some Patients With Stage IIIc to IV Ovarian Cancer
Ignace Vergote et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma
Martin Poelcher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer
K. Anwer et al.
GENE THERAPY (2010)
IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46
Maya Eisenring et al.
NATURE IMMUNOLOGY (2010)
Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois et al.
CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo
Stephanie K. Watkins et al.
JOURNAL OF IMMUNOLOGY (2007)
Biodistribution and Cearance Following Intraperitoneal Injection of Murine Interleukin-12 Plasmid Formulated with a Novel Polymeric Delivery System
Elaine Brunhoeber et al.
MOLECULAR THERAPY (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer
JG Fewell et al.
JOURNAL OF CONTROLLED RELEASE (2005)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
分享论文
